Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-01-02
2007-01-02
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S136100, C424S141100, C424S143100, C424S153100, C424S154100, C424S173100, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
10428662
ABSTRACT:
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5695755 (1997-12-01), Papayannopoulou
patent: 5824304 (1998-10-01), Papayannopoulou
patent: 5859205 (1999-01-01), Adair et al.
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 0 120 694 (1984-10-01), None
patent: 0 125 023 (1984-11-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 519 596 (1992-12-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 86/05807 (1986-10-01), None
patent: WO 87/04462 (1987-07-01), None
patent: WO 89/01036 (1989-02-01), None
patent: WO 89/07454 (1989-08-01), None
patent: WO 89/10404 (1989-11-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/04381 (1992-03-01), None
patent: WO/95/19790 (1995-07-01), None
Ulrich H. von Andrian et al. N Engl J Med 348;68-72 (2003).
L. C. Burkly, et al. Eur. J. Immunol. 1991, 21;2871-2875.
Saldanha JW et al. Mol Immunol Aug. 1999:36(11-12):709-19 (Abstract Only).
Bebbington et al. (1992) “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using A Glutamine Synthetase Gene as an Amplifiable Selectable Marker”Bio/Technology10:169-175.
Bednarczyk and McIntyre (1990) “A Monoclonal Antibody to VLAα Chain (CDw49d) Induces Homotypic Lymphocyte Aggregation”J. Immunol. 144:777-784.
Begent et al. (1990) “Phase I/II Study of Chimeric B72.3 Antibody in Radioimmunology of Colorectal Carcinoma”Br. J. Cancer62:487.
Bevilacqua et al. (1989) “Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lecins”Science243:1160-1165.
Bevilacqua et al. (1987) “Identification of an Inducible Endothelial-Leukocyte Adhesion Molecule”Proc. Natl. Acad. Sci. USAB4:9238-9242.
Bochner et al. (1991) “Adhesion of Human Basophils, Eosinophils, and Neutrophils to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules”J. Exp. Med. 173:1553-1556.
Borrebaeck et al. (1990) “The Use ofIn VitroImmunization, Cloning of Variable Regions, and SCID Mice for the Production of Human Monoclonal Antibodies” inTherapeutic Monoclonal Antibodies, Borrebaeck and Larrick (eds.), Stockton Press, Chp. 1: 1-15.
Boyd et al. (1988) “Intercellular Adhesion Molecule 1 (ICAM-1) has a Central Role in Cell—Cell Contact-Mediated Immune Mechanisms”Proc. Natl. Acad. Sci. USA85:3095-3099.
Brüggemann et al. (1989) “The Immunogenicity of Chimeric Antibodies”J. Exp. Med. 170:2153-2157.
Carlos et al. (1990) “Vascular Cell Adhesion Molecule-1 Mediates Lymphocyte Adherence to Cytokine-Activated Cultured Human Endothelial Cells”Blood76:965-970.
Clayberger et al. (1987) “Identification and Characterization of Two Novel Lymphocyte Function-Associated Antigens, L24 and L25”J. Immunol. 138:1510-1514.
Co et al. (1991) “Humanized Antibodies for Antiviral Therapy”Proc. Natl. Acad. Sci. USA88:2869-2873.
Collins et al. (1986) “Recombinant Human Tumor Necrosis Factor Increases mRNA Levels and Surface Expression of HLA-A,B Antigens in Vascular Endothelial Cells and Dermal FibroblastsIn Vitro” Proc. Natl. Acad. Sci. USA83:446-450.
Cybulsky and Gimbrone, Jr. (1991) “Endothelial Expression of a Mononuclear Leukocyte Adhesion Moleculear Leukocyte Adhesion Molecule During Atherogenesis”Science251:788-791.
Dobrina et al. (1991) “Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells”J. Clin. Invest. 88:20-26.
Dustin and Springer (1988), “Lymphocyte Function-Associated Antigen-1 (LFA-1) Interaction with Intercellular Adhesion Molecular-1 (ICAM-1) is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells”J. Cell. Biol. 107:321-331.
Dustin et al. (1986) “Induction by IL 1 and Interferonγ: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecular (ICAM-1)”J. Immunol. 137:245-254.
Edgington (1992) “How Sweet It Is: Selectin-Mediating Drugs”Bio/Technology10:383-384.
Elices et al. (1990) “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA4 at a Site Distinct from the VLA4/Fibronectin Binding Site”Cell60:577-584.
Favoloro et al. (1980) “Transcriptional Maps of Polyoma Virus Specific RNA: Analysis by Two-Dimensional Nuclease S1 Gel Mapping”Methods in Enzymology65:718-749.
Flanagan and Rabbitts (1982) “Arrangement of Human Immunoglobulin Heavy Chain Construct Region Genes Implies Evolutionary Amplification of a Segment Contaning γ, ε and α Genes”Nature300:709-713.
Freedman et al. (1990) “Adhesion of Human B Cells to Germinal Centers In Vitro Involves VLA-4 and INCAM-110”Science249:1030-1033.
Hale et al. (1988) “Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H”,Lancet(Dec. 17, 1988) 1394-1398.
Harlan (1985) “Leukocyte-Endothelial Interactions”Blood65:513-526.
Harris and Emery (1993) “Therapeutic antibodies—the coming of age”TIBTECH11: 42-44.
Hemler (1990) “VLA Proteins in the Integrin Family: Structures, Functions and Their Role on Leukocytes”Annu. Rev. Immunol. 8:365-400.
Hemler et al. (1987) “Characterization of the Cell Surface Heterodimer VLA4 and Related Peptides”J. Biol. Chem. 262:11478-11485.
Hession et al. (1991) “Cloning of an Alternate Form of Vascular Cell Adhesion Molecule-1 (VCAM1)”J. Biol. Chem. 266:6682-6685.
Hieter et al. (1980) “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments”Cell22:197-207.
Ho et al. (1989) “Site-Directed Mutagenesis by Overlap Extension Using The Polymerase Chain Reaction”Gene77:51-59.
Holzmann et al. (1989) “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α”Cell56:37-46.
Huse et al. (1989) “Generation of a Large Combinatorial Library of Immunoglobulin Repertoire in Phage Lambda”Science246:1275-1281.
Hynes (1987) “Integrins: A Family of Cell Surface Receptors”Cell48:549-554.
Issekutz (1991) “Inhibition Of In Vivo Lymphocyte Migration To Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody”J. Immunol. 147:4178-4184.
Jones and Bendig (1991) “Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions”Bio/Technology9:88-89.
Kilmartin et al. (1982) “Rat Monoclonal Antitubulin Antibodies Derived by Using a New Non-Secreting Rat Cell Line”J. Cell. Biol. 93:576-582.
Kishimoto et al. (1989) “The Leukocyte Integrins”Adv. Immunol. 46:149-182.
Köhler and Milstein (1975) “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”Nature265:495-497.
Leeuwenberg et al. (1989) “Induction of an Activation Antigen on Human Endothelial Cellsin vitro” Eur. J. Immunol. 19:715-729.
Lobb et al. (19
Carr Frank J.
Lobb Roy R.
Tempest Philip R.
Biogen Idec MA Inc.
Gambel Phillip
LandOfFree
Treatment for inflammatory bowel disease with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for inflammatory bowel disease with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for inflammatory bowel disease with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806278